checkAd

Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting

GAITHERSBURG, Md., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company will be presenting at two upcoming scientific conferences in November 2022:

  • American Heart Association Scientific Sessions 2022, Chicago, IL
    Saturday, November 5, 2022
    Poster Presentation at 11:00 am Central Time
    Title: Effect of Pemvidutide (ALT-801), a Novel GLP-1/Glucagon Dual Receptor Agonist, on Pathogenic Lipid Mediators
    Lead Author: Jorge Plutzky, MD, Director, Preventive Cardiology, Brigham and Women’s Hospital
  • American Association for the Study of Liver Disease, The Liver Meeting, Washington, DC
    Monday, November 7, 2022
    Poster Presentation at 1:00 pm Eastern Time
    Title: Effects of a Balanced GLP-1/Glucagon Receptor Dual Agonist on Reduction of Liver Fat and Weight Loss: Results of a Phase 1b Multicenter, Randomized, Double-blind, Placebo-controlled Trial in Patients with Non-alcoholic Fatty Liver Disease
    Lead Author: Stephen A. Harrison, MD, Medical Director, Pinnacle Research

A copy of the presentation materials will be accessible on the Events section of the Altimmune website.

About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Altimmune Investor & Media Contact:

Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com




Wertpapier



0 Kommentare
Nachrichtenquelle: globenewswire
 |  172   |   |   

Schreibe Deinen Kommentar

Disclaimer

Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting GAITHERSBURG, Md., Oct. 28, 2022 (GLOBE NEWSWIRE) - Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company will be presenting at two upcoming scientific conferences in November 2022: American …

Nachrichten des Autors

288 Leser
228 Leser
228 Leser
220 Leser
216 Leser
628 Leser
564 Leser
564 Leser
532 Leser
488 Leser
1628 Leser
1392 Leser
856 Leser
828 Leser
784 Leser
10525 Leser
4340 Leser
3416 Leser
2744 Leser
2246 Leser